Stem Cells Spin (WAR:SCS) Cash-to-Debt : 4.00 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Stem Cells Spin Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Stem Cells Spin's cash to debt ratio for the quarter that ended in Mar. 2024 was 4.00.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Stem Cells Spin could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Stem Cells Spin's Cash-to-Debt or its related term are showing as below:

WAR:SCS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.09 Max: No Debt
Current: 4

During the past 13 years, Stem Cells Spin's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.09.

WAR:SCS's Cash-to-Debt is ranked worse than
57.64% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs WAR:SCS: 4.00

Stem Cells Spin Cash-to-Debt Historical Data

The historical data trend for Stem Cells Spin's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Stem Cells Spin Cash-to-Debt Chart

Stem Cells Spin Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.01

0.03

1.09

0.18

2.33

Stem Cells Spin Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.02	No Debt	3.00	2.33	4.00

Competitive Comparison of Stem Cells Spin's Cash-to-Debt

For the Biotechnology subindustry, Stem Cells Spin's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stem Cells Spin's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Stem Cells Spin's Cash-to-Debt falls into.

Stem Cells Spin Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Stem Cells Spin's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.007	/	(0	+	0.003)
	=	2.33

Stem Cells Spin's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.012	/	(0	+	0.003)
	=	4.00

Stem Cells Spin (WAR:SCS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Stem Cells Spin Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Stem Cells Spin's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Stem Cells Spin (WAR:SCS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stem Cells Spin SA (WAR:SCS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141

Website

http://stemcellsspin.com.pl

Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.